Anna Mies

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Journal: Leukemia
Published: February 18, 2022

Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes.

Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes.

Journal: Scientific reports
Published: September 08, 2021

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.

Journal: Leukemia
Published: December 07, 2020

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.

Journal: American journal of hematology
Published: October 21, 2020

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Journal: Leukemia
Published: July 22, 2019

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Journal: Annals of hematology
Published: February 12, 2019

Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides.

Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides.

Journal: Haematologica
Published: February 02, 2019

Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data.

Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data.

Journal: Leukemia research
Published: February 01, 2018

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Journal: Leukemia
Published: July 11, 2017

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.

Journal: Seminars in hematology
Published: June 22, 2017

Myelodysplastic syndromes and bone loss in mice and men.

Myelodysplastic syndromes and bone loss in mice and men.

Journal: Leukemia
Published: January 12, 2017

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Journal: Leukemia & lymphoma
Published: September 24, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026